Actively Recruiting
The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients
Led by The Third Xiangya Hospital of Central South University · Updated on 2026-03-25
35
Participants Needed
1
Research Sites
261 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate the Efficacy and Safety of the Combination of Sintilimab With Platinum-doublet Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients
CONDITIONS
Official Title
The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Willing and able to comply with study visits, treatment plans, laboratory tests, and other study requirements
- Aged between 18 and 75 years old, male or female
- Diagnosed with Stage III non-small cell lung cancer confirmed by histology or cytology
- Determined by multidisciplinary team that surgical resection is not possible
- No sensitive mutations in main driver genes (EGFR, ALK, ROS1, MET, HER2, etc.)
- No prior systemic anti-tumor treatment or chest radiotherapy for NSCLC
- At least one measurable lesion suitable for repeated and accurate measurements according to RECIST v1.1
- Sufficient organ function reserve to meet clinical research needs
You will not qualify if you...
- Presence of small cell carcinoma components or special types such as salivary gland type and SMARCA4 deficiency
- Other malignant tumors within 5 years prior to enrollment, except certain cured local tumors like basal or cutaneous squamous cell carcinoma, superficial bladder cancer, cervical or breast cancer in situ
- Previous local treatments to tumor lesions such as thoracic radiotherapy or radiofrequency ablation
- Use of non-specific immunomodulatory therapy within 2 weeks before first administration or certain traditional Chinese medicines within 1 week
- Active autoimmune diseases requiring systemic treatment within past 2 years
- History of immunodeficiency, positive HIV antibodies, or long-term use of systemic corticosteroids or immunosuppressants
- Known active pulmonary tuberculosis or syphilis infection
- History of allogeneic organ or hematopoietic stem cell transplantation
- Previous or current non-infectious pneumonia or interstitial lung disease requiring systemic corticosteroids
- Serious infection requiring hospitalization within 4 weeks prior to first administration or active infections treated within 2 weeks
- Active hepatitis B infection with specified viral load thresholds
- Tumor invasion or compression of important organs or risk of fistula formation
- History of myocarditis, cardiomyopathy, or malignant arrhythmia
- History of severe gastrointestinal conditions within 6 months prior to first administration
- Recent arterial or venous thromboembolic events or uncontrolled hypertension
- History of severe bleeding or coagulation disorders
- Receipt of live vaccine within 30 days prior to first administration or planned during study
- Known allergy to any anti-tumor drug component or history of severe hypersensitivity to monoclonal antibodies
- History of mental illness, drug abuse, alcoholism, or drug use
- Pregnant or lactating women
- Any other diseases, treatments, or lab abnormalities that could affect study results or participation
- Non-malignant diseases causing higher medical risks or uncertainty in survival evaluation such as marked weight loss or high white blood cell count
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Xiangya 3rd Hospital, Central South University
Changsha, Hunan, China, 410013
Actively Recruiting
Research Team
X
XueWen Liu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here